-
公开(公告)号：US09402828B2
公开(公告)日：2016-08-02
申请号：US14592968
申请日：2015-01-09
Applicant: University Health Network
Inventor： Guohua Pan , Jacqueline M. Mason , Xin Wei , Miklos Feher
IPC: A61K31/553 , A61K31/00 , A61K31/535 , C07D273/00 , C07D211/00 , A61K31/416 , A61K31/4439 , A61K31/497 , A61K31/495 , A61K31/496 , A61K31/5377
CPC classification number: A61K31/416 , A61K31/4439 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/5377
Abstract: Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist.
Abstract translation: 本文提供了用于治疗癌症患者的方法和组合物，其中癌症的特征在于PTEN基因突变和/或PI3K基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物。
-
公开(公告)号：US08999968B2
公开(公告)日：2015-04-07
申请号：US13935016
申请日：2013-07-03
Applicant: University Health Network
Inventor： Peter Brent Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Guohua Pan
IPC: A61K31/551 , A61K31/553 , A61K31/5377 , A61K31/496 , A61K31/4427 , A61K31/416 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D471/04 , A61K31/437 , A61K45/06 , C07D471/10
CPC classification number: A61K31/553 , A61K31/416 , A61K31/437 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10
Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Abstract translation: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。
-
Patent Agency Ranking
公开(公告)号：US20140045838A1
公开(公告)日：2014-02-13
申请号：US13935021
申请日：2013-07-03
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Peter Brent Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
IPC: C07D403/04 , A61K45/06 , C07D413/14 , A61K31/5377
CPC classification number: C07D403/10 , A61K31/5377 , A61K45/06 , C07D231/56 , C07D403/04 , C07D403/14 , C07D413/14
Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Abstract translation: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。
-
公开(公告)号：US20140045822A1
公开(公告)日：2014-02-13
申请号：US13935016
申请日：2013-07-03
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Peter Brent Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Guohua Pan
IPC: A61K31/553 , C07D403/04 , A61K31/437 , C07D471/10 , A61K45/06 , C07D401/14 , A61K31/5377 , C07D409/14 , C07D471/04 , A61K31/416 , A61K31/496
CPC classification number: A61K31/553 , A61K31/416 , A61K31/437 , A61K31/496 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D471/10
Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Abstract translation: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。
-
公开(公告)号：US20140086938A1
公开(公告)日：2014-03-27
申请号：US13946221
申请日：2013-07-19
Applicant: University Health Network
Inventor： Guohua Pan
IPC: A61K31/713 , A61K45/06 , A61K31/416
CPC classification number: A61K31/713 , A61K31/00 , A61K31/416 , A61K39/39558 , A61K45/06 , A61K48/00 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/53 , G01N33/574 , G01N33/57415 , G01N2333/91215 , G01N2800/50 , G01N2800/52 , A61K2300/00
Abstract: The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject.
Abstract translation: 本发明涉及通过施用治疗有效量的TTK拮抗剂来治疗哺乳动物受试者中的TTK阳性乳腺癌或软组织肉瘤的方法。 本发明还提供了包含TTK拮抗剂和HER-2拮抗剂的组合物，以及诊断基底样乳腺癌的方法和通过评估TTK在肿瘤样品中的表达来确定患有癌症的受试者的预后的方法 课程。
-
公开(公告)号：US20160045511A1
公开(公告)日：2016-02-18
申请号：US14823057
申请日：2015-08-11
Applicant: University Health Network
Inventor： Peter Brent Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
IPC: A61K31/5377
CPC classification number: C07D403/10 , A61K31/5377 , A61K45/06 , C07D231/56 , C07D403/04 , C07D403/14 , C07D413/14
Abstract: The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Abstract translation: 本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。 本文提供了结构式中变量的定义。
-
公开(公告)号：US20150182504A1
公开(公告)日：2015-07-02
申请号：US14592968
申请日：2015-01-09
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： Guohua Pan , Jacqueline M. Mason , Xin Wei , Miklos Feher
IPC: A61K31/416 , A61K31/4439 , A61K31/5377 , A61K31/496
CPC classification number: A61K31/416 , A61K31/4439 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/5377
Abstract: Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist.
Abstract translation: 本文提供了用于治疗癌症患者的方法和组合物，其中癌症的特征在于PTEN基因突变和/或PI3K基因突变。 在具体实施方案中，所述方法包括向患者施用包含治疗有效量的PLK4拮抗剂的组合物。
-
-
-
-
-
-
Search Results
7
records
(took 0.036 seconds)
